4D Molecular Therapeutics Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific

Reuters

2025/10/31

<a href="https://laohu8.com/S/FDMT">4D Molecular Therapeutics</a> Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific

4D Molecular Therapeutics Inc. (4DMT) announced an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific region, including Japan. Under the terms of the agreement, 4DMT will receive an upfront cash payment of $85 million and is expected to receive at least $50 million in cost sharing from Otsuka over the next three years to support global development activities. The agreement also includes up to $336 million in potential regulatory and commercial milestone payments, along with tiered double-digit royalties based on net sales in Otsuka's territories. 4DMT retains full development and commercialization rights for 4D-150 outside the APAC region, including the U.S., Latin America, and Europe. Proceeds and cost sharing from this agreement are expected to support a global Phase 3 clinical trial in diabetic macular edema (DME) and pre-commercial activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566023-en) on October 31, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579484402"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579484402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579484402?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 11:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579484402","market":"us","top_or_hot":-1,"title":"4D Molecular Therapeutics Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        4D Molecular <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. (4DMT) announced an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific region, including Japan. Under the terms of the agreement, 4DMT will receive an upfront cash payment of $85 million and is expected to receive at least $50 million in cost sharing from Otsuka over the next three years to support global development activities. The agreement also includes up to $336 million in potential regulatory and commercial milestone payments, along with tiered double-digit royalties based on net sales in Otsuka's territories. 4DMT retains full development and commercialization rights for 4D-150 outside the APAC region, including the U.S., Latin America, and Europe. Proceeds and cost sharing from this agreement are expected to support a global Phase 3 clinical trial in diabetic macular edema (DME) and pre-commercial activities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566023-en) on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4D Molecular Therapeutics Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4D Molecular Therapeutics Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 11:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        4D Molecular <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. (4DMT) announced an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific region, including Japan. Under the terms of the agreement, 4DMT will receive an upfront cash payment of $85 million and is expected to receive at least $50 million in cost sharing from Otsuka over the next three years to support global development activities. The agreement also includes up to $336 million in potential regulatory and commercial milestone payments, along with tiered double-digit royalties based on net sales in Otsuka's territories. 4DMT retains full development and commercialization rights for 4D-150 outside the APAC region, including the U.S., Latin America, and Europe. Proceeds and cost sharing from this agreement are expected to support a global Phase 3 clinical trial in diabetic macular edema (DME) and pre-commercial activities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566023-en) on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL52QjX7:1","article_id":"2579484402","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579484402","pubTimestamp":1761879746,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"4D Molecular Therapeutics Inc.  announced an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific region, including Japan. Under the terms of the agreement, 4DMT will receive an upfront cash payment of $85 million and is expected to receive at least $50 million in cost sharing from Otsuka over the next three years to support global development activities. The agreement also includes up to $336 million in potential regulatory and commercial milestone payments, along with tiered double-digit royalties based on net sales in Otsuka's territories. 4DMT retains full development and commercialization rights for 4D-150 outside the APAC region, including the U.S., Latin America, and Europe. Proceeds and cost sharing from this agreement are expected to support a global Phase 3 clinical trial in diabetic macular edema  and pre-commercial activities.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","FDMT":"4D Molecular Therapeutics","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"4D Molecular Therapeutics与Otsuka签订亚太地区4D-150许可协议，预付8500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FDMT":0.9,"NDAQ":0.9},"content_text":"4D Molecular Therapeutics Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific\n    \n\n        4D Molecular Therapeutics Inc. (4DMT) announced an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific region, including Japan. Under the terms of the agreement, 4DMT will receive an upfront cash payment of $85 million and is expected to receive at least $50 million in cost sharing from Otsuka over the next three years to support global development activities. The agreement also includes up to $336 million in potential regulatory and commercial milestone payments, along with tiered double-digit royalties based on net sales in Otsuka's territories. 4DMT retains full development and commercialization rights for 4D-150 outside the APAC region, including the U.S., Latin America, and Europe. Proceeds and cost sharing from this agreement are expected to support a global Phase 3 clinical trial in diabetic macular edema (DME) and pre-commercial activities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566023-en) on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}